GEN Exclusives

More »

GEN News Highlights

More »
Oct 27, 2010

Myriad to Conduct BRCA Mutation Testing for Abbott’s Phase III Study

  • Myriad Genetics signed an agreement with Abbott Laboratories to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multicenter, global study for the treatment of metastatic breast cancer. While the companies are not divulging the drug candidate under investigation, they say that a deal was previously signed covering Phase II testing of the same drug.

    Myriad will use its BRACAnalysis® test to identify the presence of germline mutations in breast cancer patients to be enrolled in the study. It will determine the mutation status and provide standard test reports to the clinicians at each study site.

    BRACAnalysis was developed by Myriad Genetics to assess a woman’s risk for hereditary breast and ovarian cancer. A woman who tests positive with BRACAnalysis has, on average, an 82% risk of developing breast cancer during her lifetime and a 44% risk of developing ovarian cancer, the company explains.

    The company points to research published in the Journal of the National Cancer Institute that has shown presymptomatic individuals who have a high risk of developing breast cancer can reduce their risk by approximately 50% with appropriate preventive therapies. They also note work published in The New England Journal of Medicine that has shown presymptomatic individuals who carry gene mutations can lower their risk of developing ovarian cancer by approximately 60% with appropriate preventive therapies.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?